Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders

A. Olivieri, I. Scortechini, D. Capelli, M. Montanari, M. Lucesole, G. Gini, M. Troiani, M. Offidani, A. Poloni, M. C. Masia, G. M. Raggetti, P. Leoni

Research output: Contribution to journalArticle

Abstract

We compared the use of G-CSF plus EPO in a group of 32 multiple myeloma and lymphoma patients with historical controls receiving G-CSF alone. Haemopoietic reconstitution was significantly faster in patients receiving G-CSF + EPO (group B), with a median time of 10 days to achieve an ANC count >0.5 × 109/l, compared to 11 days in the historical group (A). The median duration of severe neutropenia (ANC count 20 × 109 and >50 × 109/l were achieved at days + 13 and + 17, respectively in group B, compared to days + 14 and + 24, respectively, in group A (P = 0.015, 0.002) patients. The transfusion requirement was reduced in group B, with 0 (0-6) RBC units and 1 (0-5) platelet unit transfused in group B vs 2 RBC (0-9) and 2 platelet units (0-8) in group A. Median days of fever, antibiotic therapy and hospital stay were reduced in group B (9.5 days vs 22). The mean cost of autotransplantation per group A patient was 23 988 Euro, compared with 18 394 Euro for a group B patient. Our study suggests that the EPO + G-CSF combination not only accelerates engraftment kinetics, but can also improve the clinical course of ASCT.

Original languageEnglish
Pages (from-to)693-702
Number of pages10
JournalBone Marrow Transplantation
Volume34
Issue number8
DOIs
Publication statusPublished - Oct 2004

Keywords

  • Autologous transplantation
  • Engraftment kinetics
  • Erythropoietin

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders'. Together they form a unique fingerprint.

  • Cite this

    Olivieri, A., Scortechini, I., Capelli, D., Montanari, M., Lucesole, M., Gini, G., Troiani, M., Offidani, M., Poloni, A., Masia, M. C., Raggetti, G. M., & Leoni, P. (2004). Combined administration of alpha-erythropoietin and filgrastim can improve the outcome and cost balance of autologous stem cell transplantation in patients with lymphoproliferative disorders. Bone Marrow Transplantation, 34(8), 693-702. https://doi.org/10.1038/sj.bmt.1704643